Leave Your Message

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

AI Helps Write
AI Helps Write
Nā Māhele Lapaʻau
Nā Hana Lapaʻau i Hōʻike ʻia

CAR-T no ka maʻi Leukemia Lymphoblastic B-cell ʻoʻoleʻa (B-ALL)

    ʻIke laulā

    ʻO B-ALL (Acute B-cell Lymphoblastic Leukemia) kahi ʻano leukemia ikaika, e hoʻopilikia nui ana i nā keiki a me nā ʻōpio. ʻOiai ka holomua ʻana o ka chemotherapy kuʻuna, nui nā maʻi e ʻike i ka relapse a i ʻole ke kūʻē ʻana i ka lāʻau. ʻO ka CAR-T (Chimeric Antigen Receptor T-cell) therapy ke ʻano o kahi immunotherapy groundbreaking i hōʻike i ka holomua kupaianaha i ka mālama ʻana i ka relapsed a refractory paha B-ALL, e hāʻawi ana i ka manaʻolana no nā maʻi i loaʻa mua nā koho lapaʻau palena.

    He aha ka lāʻau lapaʻau CAR-T?

    ʻO ka lāʻau lapaʻau CAR-T kahi lāʻau lapaʻau holomua a pilikino e pili ana i ka hoʻololi ʻana i nā T-cell ponoʻī o ka mea maʻi e ʻike a hoʻouka i nā cell cancer. No B-ALL, ua hana ʻia nā CAR-T cell e kuhikuhi i ka antigen CD19, kahi protein i loaʻa pinepine ma ka ʻili o nā cell leukemia B-cell. Ke hoʻokomo hou ʻia i loko o ke kino o ka mea maʻi, ʻimi kēia mau T-cell i hana ʻia a luku i nā cell leukemia, e alakaʻi ana paha i ke kala ʻana no ka manawa lōʻihi.

    Nā Pōmaikaʻi Koʻikoʻi o ka CAR-T Therapy no B-ALL

    • Ka Pono KiʻekiʻeUa hōʻike ʻo CAR-T therapy i ka holomua kupaianaha i ka mālama ʻana i ka B-ALL i hoʻihoʻi ʻia a paʻakikī paha, e hāʻawi ana i kahi kiʻekiʻe o ke kala ʻana i nā poʻe maʻi i pane ʻole i nā lāʻau lapaʻau kuʻuna.
    • Hana i Hoʻolālā ʻiaMa ka nānā ʻana i ka antigen CD19, kuhikuhi pono ka lāʻau lapaʻau CAR-T a luku i nā pūnaewele B-ALL, e hoʻemi ana i ka hōʻino ʻana i nā ʻiʻo olakino.
    • Lapaʻau pilikinoʻOiai ua loaʻa nā pūnaewele CAR-T mai ka ʻōnaehana pale ponoʻī o ka mea maʻi, ua pilikino loa ka lāʻau lapaʻau, e hoʻonui ana i kona pono a me ka hoʻemi ʻana i ka pilikia o ka hōʻole ʻia.
    • Kala ʻana PaʻaI nā hihia he nui, ua alakaʻi ka lāʻau lapaʻau CAR-T i ke kala mau loa, e hāʻawi ana i nā mea maʻi i ka hiki ke ola lōʻihi me ka emi ʻana o nā relapses.

    Kaʻina Hana Lapaʻau

    • ʻOhiʻohi o nā pūnaewele TʻO ka hana mua e pili ana i ka hōʻiliʻili ʻana i nā pūnaewele T mai ke koko o ka mea maʻi ma o ke kaʻina hana i kapa ʻia ʻo leukapheresis.
    • ʻEnekinia ʻana i nā pūnaewele THoʻololi ʻia nā pūnaewele T i hōʻiliʻili ʻia ma ke ʻano genetic i loko o ka hale hana e hōʻike i kahi mea hoʻokipa antigen chimeric (CAR) kūikawā i CD19, e hoʻonui ana i ko lākou hiki ke kuhikuhi i nā pūnaewele B-ALL.
    • Hoʻokomo ʻia ʻana o nā pūnaewele CAR-TMa hope o kahi manawa pōkole o ka hoʻonui ʻana o ke kelepona, ua hoʻihoʻi ʻia nā pūnaewele CAR-T i hana ʻia i loko o ke kino o ka mea maʻi ma o kahi hoʻokomo intravenous (IV).
    • Ka Nānā ʻana a me ka Hoʻōla ʻanaMa hope o ka hoʻokomo ʻana, nānā pono ʻia nā mea maʻi no nā hopena ʻaoʻao e like me ka cytokine release syndrome (CRS) a me ka neurotoxicity. Hiki ke hoʻokele ʻia kēia mau hopena, a hoʻōla ka hapa nui o nā mea maʻi me nā hana kūpono.

    No ke aha e koho ai i ka CAR-T Therapy a BIOOCUS no B-ALL?

    • ʻenehana hou loaHoʻohana ʻo BIOOCUS i ka ʻenehana holomua loa e hōʻoia i ka hana ʻana o nā cell CAR-T kūpono loa a me nā hopena maʻi.
    • Pūʻulu Lapaʻau AkamaiUa hoʻolaʻa ʻia kā mākou hui o nā loea i ka hematology a me ka immunotherapy i ka hāʻawi ʻana i ka mālama pilikino a me ka hoʻonui ʻana i ka holomua o kēlā me kēia lāʻau lapaʻau.
    • ʻIke HonuaHāʻawi mākou i ka lāʻau lapaʻau CAR-T i nā poʻe maʻi mai ka honua holoʻokoʻa, me kahi moʻolelo o nā lāʻau lapaʻau holomua a me ke kala ʻana no ka manawa lōʻihi no nā poʻe maʻi B-ALL.
    • Mālama pihaMai ke kūkākūkā mua ʻana a hiki i ka nānā ʻana ma hope, hāʻawi ʻo BIOOCUS i ka mālama piha piha, e hōʻoiaʻiʻo ana e loaʻa i nā mea maʻi ka lāʻau maikaʻi loa i kēlā me kēia pae.

    Nā Hōʻike Lapaʻau a me nā Kūlana Holomua

    Ua hōʻike ʻia nā hoʻokolohua lapaʻau hou a me nā ʻikepili o ke ao maoli e hāʻawi ana ka lāʻau CAR-T no B-ALL i nā hopena kūikawā, ʻoiai no nā poʻe maʻi i hoʻi hou i ka maʻi a i ʻole kūʻē i nā lāʻau kuʻuna. Ua hōʻike mau ka lāʻau lapaʻau i nā helu kala kiʻekiʻe, me ka nui o nā poʻe maʻi e loaʻa ana ke kala piha a me ka mālama ʻana i ke ola lōʻihi.

    Ma BIOOCUS, ua mālama pono mākou i nā maʻi he nui me B-ALL me ka hoʻohana ʻana i ka lāʻau lapaʻau CAR-T, a ua maikaʻi loa nā hopena. No ka hoʻomaopopo hohonu ʻana i nā moʻolelo holomua a me nā hopena maoli, e ʻoluʻolu e nānā i nā haʻawina hihia maʻi ma lalo nei:

    Hōʻike kēia mau hihia i ka hiki ke hoʻololi i ka lāʻau lapaʻau CAR-T no nā poʻe maʻi B-ALL, e hōʻike ana ʻaʻole wale i ka pono o ka lāʻau lapaʻau akā i kona hiki ke hāʻawi i nā mea maʻi i kahi manawa lua i ke ola.

    ʻIkepili Lapaʻau

    Nā hōʻailona no CD19+20CAR-T:Nā maʻi me ka lymphoma B-cell non Hodgkin

    Ka uku CR hoʻokahi mahina

    Ka uku PR hoʻokahi mahina

    Hoʻokahi mahina OR uku

    CRS≥3

    CRES≥3

    71.95%(59/82)

    25.6(21/82)

    97.55(80/82)

    12.19%(10/82)

    0

    Nā hōʻailona no CD19+22CAR-T:Ka mālama ʻana i nā maʻi leukemia B-lymphocytic acute i hoʻihoʻi ʻia mai ka CD19 a me ka refractory

    Ka uku CR hoʻokahi mahina

    Ka uku PR hoʻokahi mahina

    Hoʻokahi mahina OR uku

    CRS≥3

    CRES≥3

    92.1%(35/38)

    7.9%(3/38)

    100%(38/38)

    15.79%(6/38)

    0

    Nā hōʻailona no BCMACAR-T:Ka mālama ʻana i ka myeloma maha relapsed a me ka refractory

    Ka uku CR hoʻokahi mahina

    Ka uku PR hoʻokahi mahina

    Hoʻokahi mahina OR uku

    CRS≥3

    CRES≥3

    72.41%(21/29)

    27.59%(8/29)

    100%(29/29)

    6.9%(2/29)

    0

    Submit An Free Inquiry

    Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

    AI Helps Write